It's #WorldHealthDay, and we would like to express our gratitude for all of the #healthcareworkers out there continuing their amazing work on the front lines during this difficult time. #sepsis #covid19 #stewardship #WHO

A study in JAMA showed that administering inadequate and unnecessary broad empiric antibiotics were associated with higher mortality. #T2Bio provides results in 3-5 hours of first blood draw, often before the second dose of ABX is administered. ja.ma/2XXD1Lw

OBAMAGATE!

We are proud to announce that the #T2Bacteria Panel won the "Best New Technology Solution- Diagnostics" award in the #MedTech Breakthrough Awards Program! bit.ly/2z1TwMN #sepsis #antimicrobialresistance

A report by American Thoracic Society (ATS) states, narrowing/discontinuation of ABX is more likely to occur when the appropriate diagnostics are obtained at onset of infection. T2 panels enable physicians to target therapy within 3-5 hours of first blood draw, often before 2nd dose of ABX. #AMR

We are proud to announce the U.S. launch of our new molecular diagnostic test, the T2SARS-CoV-2 Panel, which has demonstrated excellent clinical performance in the detection of SARS-CoV-2, the virus responsible for #COVID19! bit.ly/2YLJPMd

These statistics serve as a constant reminder of why T2 Biosystems exists- to deliver life-saving innovations to achieve targeted therapy, faster! Contact us today to find out how #T2Bio can help you meet your stewardship goals and improve patient outcomes bit.ly/3fuQKiU

The T2SARS-CoV-2 Panel has been awarded Emergency Use Authorization (EUA) by the U.S. FDA. We have a robust supply chain and are not on allocation. Contact us to place an order today! bit.ly/2EVE47d #T2Bio #COVID19 #SARSCoV2 #sepsis

Elated & gratified: largest funding BARDA to date $CFRX awarded $86.8M. $9.8M initially for PH3 #exebacase superiority study in pts w/ Staph aureus & up to $77M more w/ potential FDA approval/post-approval milestones. Interim analysis slated 2nd half 2021 ir.contrafect.com/press-releases…

Along w/BARDA $, more news @ $CFRX: closed public offering of common stock - net proceeds $57.5M. Intend to fund: #exebacase #PH3, PH 1/2 of exebacase for pts w/ chronic post-op #Saureus prosthetic joint infections + #IND activity w/ PH 1a/1b #CF370 trial ir.contrafect.com/press-releases…